InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,225.53
(
0.53%
)
Post# of 251706
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119567
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 212721

Thursday, 08/03/2017 3:21:26 PM

Thursday, August 03, 2017 3:21:26 PM

Post# of 251706
FDA approves ABBV/ENTA’s Mavyret (G/P)—8-week treatment for all HCV genotypes:

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm570038.htm

ENTA will receive a milestone payment from ABBV that I estimate to be $45-50M. (The exact amount will be known when ENTA issues its own PR.)

Note: The US brand name has a "y" where the EU brand name (Maviret) has an "i".

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up